STOCK TITAN

Iovance Kirby receives 10,000 shares as grant vests

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Iovance Biotherapeutics, Inc. (IOVA) Chief Commercial Officer Daniel Gordon Kirby had 10,000 restricted stock units vest on November 10, 2026, converting into 10,000 common shares. The issuer withheld 3,935 common shares to meet mandatory tax withholding; this was not an open-market sale. The report lists 50,003 remaining RSUs from a February 10, 2025 grant, which will vest in equal quarterly installments; that count excludes any other RSUs he holds.

Insider Kirby Daniel Gordon
Role Chief Commercial Officer
Type Security Shares Price Value
Exercise Restricted Stock Units F4, F5, F6 10,000 $0.00 $0.00
Exercise Common Stock F1 10,000 $0.00 $0.00
Tax Withholding Common Stock F2, F3 3,935 $8.08 $32K
Holdings After Transaction: Restricted Stock Units — 50,003 units (Direct); Common Stock — 160,576 shares (Direct)
Holdings Before and After: Restricted Stock Units, 60,003 to 50,003 units (Direct); Common Stock, 154,511 to 160,576 shares (Direct)
Footnotes (6)
  1. F1. Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.
  2. F2. Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.
  3. F3. Represents the common stock remaining after deducting the common stock withheld for taxes.
  4. F4. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
  5. F5. The remaining RSUs will vest in equal quarterly installments.
  6. F6. Such aggregate number reflects the remainder of such RSUs granted on February 10, 2025, but does not include any other RSUs held by such Reporting Person.
Restricted stock units vested 10,000 units November 10, 2026; converted into common shares
Common shares received 10,000 shares Upon vesting on November 10, 2026
Shares withheld for taxes 3,935 shares Withheld by the issuer upon vesting on November 10, 2026
Remaining RSUs 50,003 RSUs Remainder of RSUs granted February 10, 2025; excludes any other RSUs held
restricted stock units financial
"shares underlying the restricted stock units ("RSUs") which vested"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
mandatory tax withholding requirements financial
"satisfy the mandatory tax withholding requirements upon vesting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many IOVA shares did Daniel Gordon Kirby receive when his RSUs vested?

Daniel Gordon Kirby, Iovance Biotherapeutics' Chief Commercial Officer, had 10,000 restricted stock units vest on November 10, 2026, converting into 10,000 common shares.

How many IOVA shares were withheld for taxes when the RSUs vested?

Iovance withheld 3,935 common shares to satisfy mandatory tax withholding when the RSUs vested on November 10, 2026; the reported withholding was not an open-market sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kirby Daniel Gordon

(Last)(First)(Middle)
C/O IOVANCE BIOTHERAPEUTICS, INC.
300 ROUSE BLVD.

(Street)
PHILADELPHIA PENNSYLVANIA 19112

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
IOVANCE BIOTHERAPEUTICS, INC. [ IOVA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Commercial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/10/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/10/2026(1)M10,000A$0164,511D
Common Stock11/10/2026(2)F3,935D$8.08160,576(3)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units(4)11/10/2026M10,000 (5) (5)Common Stock10,000$0.0050,003(6)D
Explanation of Responses:
1. Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.
2. Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.
3. Represents the common stock remaining after deducting the common stock withheld for taxes.
4. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
5. The remaining RSUs will vest in equal quarterly installments.
6. Such aggregate number reflects the remainder of such RSUs granted on February 10, 2025, but does not include any other RSUs held by such Reporting Person.
/s/ Daniel Gordon Kirby11/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading